

DeveloGen AG

[View the current DeveloGen AG Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/3361-DeveloGen+AG.html)

(<http://www.bioportfolio.com/biocorporate/3361-DeveloGen+AG.html>)

Contact Details:

Rudolf-Wissell-Str. 28
Göttingen

Tel: +49 (0) 551 5055861
Fax: +49 (0) 551 5055886
Email:

D-37079
Germany

DeveloGen is a leading biotechnology company developing innovative gene-based medicines. By applying novel functional genomic and gene discovery techniques to developmental biology, DeveloGen has pioneered programs in diabetes, obesity and liver regeneration. In 1999, DeveloGen and its founders were awarded the German President's prize for innovation. In May 2000, DeveloGen merged with HepaVec AG - Germany's leading gene delivery and liver disease biotechnology company. To date the company has 70 employees in its research laboratories in Göttingen and Berlin. Corporate headquarters are located in Göttingen. The merged company, which will keep the DeveloGen name, combines the rapid gene discovery and functional genomics strengths of DeveloGen, with the innovative gene delivery technology pioneered by HepaVec.

Recent Publications by DeveloGen AG:



- [Inhibition of GSK3 promotes replication and survival of pancreatic beta cells.](#)
*Recent developments indicate that the regeneration of beta cell function...*1st June, 2007
DeveloGen AG, Marie-Curie-Strasse 7, Göttingen 37079, Germany.- J Biol Chem. 2007 Apr 20;282(16):12030-7. Epub 2007 Jan 22. ([DOI Direct Link](#))
- [Obesity and related disorders--SMi's Second Annual Conference.](#)
*Recent developments indicate that the regeneration of beta cell function...*29th July, 2005
DeveloGen AG, Rudolf-Wissell Strasse 28, D-37079 Göttingen, Germany.- IDrugs. 2005 Apr;8(4):297-8.
- [Phenotype-first screening for the identification of novel drug targets.](#)
*Modern drug discovery is predominantly a target-driven process, where...*13th July, 2005
DeveloGen AG, Rudolf-Wissell-Strasse 28, 37079 Göttingen, Germany.- Drug Discov Today. 2005 Feb 15;10(4):275-82. ([DOI Direct Link](#))

- [Target discovery in metabolic disease.](#)
*The prevalence of metabolic diseases is taking on epidemic proportions and...*24th December, 2004
DeveloGen AG, Rudolf-Wissell Strasse 28, 37079 Goettingen, Germany.- Drug Discov Today. 2004 Sep 15;9(18):785-94. ([DOI Direct Link](#))
- [Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice.](#)
*Ovine atadenovirus (OAdV) is a novel gene transfer vector with excellent...*19th October, 2004
DeveloGen AG, Rudolf-Wissell-Str. 28, 37092 Gottingen, Germany.- Vaccine. 2004 Jul 29;22(21-22):2717-21. ([DOI Direct Link](#))
- [Control of triglyceride storage by a WD40/TPR-domain protein.](#)
*Obesity is a metabolic disorder related to improper control of energy...*24th September, 2004
DeveloGen AG, Rudolf-Wissell-Strasse 28, 37079 Gottingen, Germany.- EMBO Rep. 2003 May;4(5):511-6. ([DOI Direct Link](#))
- [Metabolic Diseases Drug Discovery World Summit--SRI conference. 28-29 July 2003 San Diego, CA, USA.](#)
*Gene transfer vectors derived from ovine atadenovirus type 7 (OAdV) can...*27th April, 2004
DeveloGen AG Rudolf-Wissell Strasse 28 D 37079 Goettingen, Germany.- IDrugs. 2003 Sep;6(9):845-9.
- [Identification of an ovine atadenovirus gene whose product activates the viral E2 promoter: possible involvement of E2F-1.](#)
*Activation of the adenoviral E2 promoter is an early step in adenovirus...*6th April, 2004
DeveloGen AG, 37079 Gottingen, Germany.- Virology. 2004 Jan 5;318(1):79-89. ([DOI Direct Link](#))
- [Construction, rescue, and characterization of vectors derived from ovine atadenovirus.](#)
*Gene transfer vectors derived from ovine atadenovirus type 7 (OAdV) can...*3rd December, 2003
DeveloGen- J Virol. 2003 Nov;77(22):11941-51.
- [Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications.](#)
*Various methods have been developed to transfer and express genes in...*1st October, 2003
DeveloGen AG, NL Berlin, Berlin, Germany.- Am J Pharmacogenomics. 2003;3(1):53-63.
- [Preparation of ovine adenovirus vectors.](#)
*Within the last two decades, various vectors based on human viruses have...*25th January, 2003
DeveloGen AG, NL Berlin, Berlin-Buch, Germany.- Methods Mol Med. 2002;69:415-26.
- [Biology of ovine adenovirus infection of nonpermissive cells.](#)
*Nonhuman adenoviruses, including those of the genus Atadenovirus, have the...*28th November, 2002
DeveloGen AG, Niederlassung Berlin, 13125 Berlin, Germany.- J Virol. 2002 Nov;76(21):10882-93.

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service

- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

